Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein–Based Vaccine Adjuvanted With Glucopyranosyl Lipid A–Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge

De Anna J. Friedman-Klabanoff, Andrea A. Berry, Mark A. Travassos, Mallory Shriver, Catherine Cox, Jessica Butts, Jordan S. Lundeen, Kathleen A. Strauss, Sudhaunshu Joshi, Biraj Shrestha, Annie X. Mo, Effie Y.H. Nomicos, Gregory A. Deye, Jason A. Regules, Elke S. Bergmann-Leitner, Marcela F. Pasetti, Matthew B. Laurens*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Recombinant Full-length Plasmodium falciparum Circumsporozoite Protein–Based Vaccine Adjuvanted With Glucopyranosyl Lipid A–Liposome Quillaja saponaria 21: Results of Phase 1 Testing With Malaria Challenge'. Together they form a unique fingerprint.

Medicine & Life Sciences